University of chicago prostate cancer treatment, Doctors may have found secretive new organs in the center of your head

Karcsoport címke: Arm II enzalutamide Másik név: Xtandi Jogosultság Kritériumok: Inclusion Criteria: - Have diagnosis of prostate cancer and have received treatment with GnRH agonist or antagonist therapy for at least 1 month prior to enrollment. This stipulation is in place because not all of the proposed quality of life or cognitive tests are available or validated in other languages.

Prior to enrollment, patients may have received treatment with abiraterone acetate or enzalutamide for no more than 14 days before completing baseline studies. At least 12 months must have elapsed since completion of chemotherapy.

At least 60 days must have elapsed since completion of definitive radiation therapy or surgery and patient must have only grade 2 or less adverse effects at the time of registration.

Patients are not considered to have a "currently active" malignancy if they have completed all therapy and are now considered without evidence of disease for 1 year. Patients with cognitive dysfunction related to treatment of another malignancy, including a history of "chemo-brain", are ineligible.

Appropriate treatment by a licensed provider with medications for depression or anxiety, including but not limited to SSRIs, SNRIs, and standard dose benzodiazepines at a stable dose, is permitted Nem:.